Media
Press Releases
August 14, 2024
Lupin Receives Tentative Approval from U.S. FDA for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC)
August 5, 2024
Lupin Receives Approval from U.S. FDA for Prednisolone Acetate Ophthalmic Suspension USP
July 31, 2024
Lupin Receives Approval from U.S. FDA for Emtricitabine and Tenofovir Alafenamide Tablets
July 27, 2024
Lupin Receives Tentative Approval from U.S. FDA for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
July 19, 2024
Lupin’s Alliance Partner ForDoz Receives U.S. FDA Approval for Doxorubicin Hydrochloride Liposome Injection
July 16, 2024
Lupin Receives Tentative Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets
July 12, 2024
Lupin Receives EIR from U.S. FDA for its Dabhasa Facility
July 12, 2024
Lupin Receives Approval from U.S. FDA for Topiramate Extended-Release Capsules
July 9, 2024
Lupin Receives Tentative Approval from U.S. FDA for Empagliflozin, Linagliptin and Metformin Hydrochloride Extended-Release Tablets
Media
Rajalakshmi Azariah
Vice President & Global Head - Corporate Communications
rajalakshmiazariah@lupin.comSmart Guide
Close
CloseSearch Product